Your browser doesn't support javascript.
Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization.
Ebenig, Aileen; Muraleedharan, Samada; Kazmierski, Julia; Todt, Daniel; Auste, Arne; Anzaghe, Martina; Gömer, André; Postmus, Dylan; Gogesch, Patricia; Niles, Marc; Plesker, Roland; Miskey, Csaba; Gellhorn Serra, Michelle; Breithaupt, Angele; Hörner, Cindy; Kruip, Carina; Ehmann, Rosina; Ivics, Zoltan; Waibler, Zoe; Pfaender, Stephanie; Wyler, Emanuel; Landthaler, Markus; Kupke, Alexandra; Nouailles, Geraldine; Goffinet, Christine; Brown, Richard J P; Mühlebach, Michael D.
  • Ebenig A; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Muraleedharan S; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Kazmierski J; Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Todt D; Department for Molecular and Medical Virology, Ruhr-University, 44801 Bochum, Germany; European Virus Bioinformatics Center (EVBC), 07743 Jena, Germany.
  • Auste A; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany; German Center for Infection Research, Gießen-Marburg-Langen, Germany.
  • Anzaghe M; Div. of Immunology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Gömer A; Department for Molecular and Medical Virology, Ruhr-University, 44801 Bochum, Germany; Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
  • Postmus D; Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Gogesch P; Div. of Immunology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Niles M; Div. of Immunology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Plesker R; Animal Facilities, Div. Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Miskey C; Div. of Medical Biotechnology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Gellhorn Serra M; Institute for Virology, Phillipps-University, 35043 Marburg, Germany.
  • Breithaupt A; Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald-Insel Riems, Germany.
  • Hörner C; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany; German Center for Infection Research, Gießen-Marburg-Langen, Germany.
  • Kruip C; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Ehmann R; Institute for Microbiology, Bundeswehr, 80937 München, Germany.
  • Ivics Z; Div. of Medical Biotechnology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Waibler Z; Div. of Immunology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Pfaender S; Department for Molecular and Medical Virology, Ruhr-University, 44801 Bochum, Germany.
  • Wyler E; Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 10115 Berlin, Germany.
  • Landthaler M; Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 10115 Berlin, Germany; IRI Life Sciences, Institute for Biology, Humboldt-Universität zu Berlin, 10115 Berlin, Germany.
  • Kupke A; German Center for Infection Research, Gießen-Marburg-Langen, Germany; Institute for Virology, Phillipps-University, 35043 Marburg, Germany.
  • Nouailles G; Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Frei
  • Goffinet C; Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Brown RJP; Virus Tropism and Immunogenicity, Div. of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.
  • Mühlebach MD; Product Testing of IVMPs, Div. of Veterinary Medicines, Paul-Ehrlich-Institut, 63225 Langen, Germany; German Center for Infection Research, Gießen-Marburg-Langen, Germany. Electronic address: michael.muehlebach@pei.de.
Cell Rep ; 40(7): 111214, 2022 08 16.
Artículo en Inglés | MEDLINE | ID: covidwho-1966424
ABSTRACT
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a severe hamster infection model a T helper type 1 (TH1)-biased measles vaccine-derived candidate and a TH2-biased alum-adjuvanted, non-stabilized spike protein. The measles virus (MeV)-derived vaccine protects the animals, but the protein lead induces VAERD, which can be alleviated by dexamethasone treatment. Bulk transcriptomic analysis reveals that our protein vaccine prepares enhanced host gene dysregulation in the lung, exclusively up-regulating mRNAs encoding the eosinophil attractant CCL-11, TH2-driving interleukin (IL)-19, or TH2 cytokines IL-4, IL-5, and IL-13. Single-cell RNA sequencing (scRNA-seq) identifies lung macrophages or lymphoid cells as sources, respectively. Our findings imply that VAERD is caused by the concerted action of hyperstimulated macrophages and TH2 cytokine-secreting lymphoid cells and potentially links VAERD to antibody-dependent enhancement (ADE). In summary, we identify the cytokine drivers and cellular contributors that mediate VAERD after TH2-biased vaccination.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Estudio experimental Tópicos: Vacunas Límite: Animales Idioma: Inglés Revista: Cell Rep Año: 2022 Tipo del documento: Artículo País de afiliación: J.celrep.2022.111214

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Estudio experimental Tópicos: Vacunas Límite: Animales Idioma: Inglés Revista: Cell Rep Año: 2022 Tipo del documento: Artículo País de afiliación: J.celrep.2022.111214